All In Biotech

Drug Trial Radar · NCT01836523

The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes

The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial

Last checked: Nov 19, 2026Latest source record: Mar 6, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,398 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,398

Actual

Start

Nov 2013

Primary completion

Jun 2015

Study completion Jun 2015

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Apr 22, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is conducted globally. The aim of the trial is to confirm the efficacy and safety of liraglutide as adjunct therapy to insulin in the treatment of type 1 diabetes. The total trial duration per subject is approximately 58 weeks.

Conditions

  • Diabetes
  • Diabetes Mellitus, Type 1

Interventions

  • liraglutideDrug

    Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.

  • placeboDrug

    Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.

  • liraglutideDrug

    Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.

  • placeboDrug

    Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.

  • liraglutideDrug

    Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.

  • placeboDrug

    Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in HbA1c (Glycosylated Haemoglobin)Time frame: Week 0, week 52
  2. Change From Baseline in Body WeightTime frame: Week 0, week 52
  3. Change From Baseline in Total Daily Insulin DoseTime frame: Week 0, week 52

Locations

182 sites in 17 countries. Site status is shown where the registry gives one.

  • Novo Nordisk Investigational Site

    Little Rock, Arkansas

  • Novo Nordisk Investigational Site

    Concord, California

  • Novo Nordisk Investigational Site

    Encino, California

  • Novo Nordisk Investigational Site

    Escondido, California

  • Novo Nordisk Investigational Site

    Huntington Beach, California

  • Novo Nordisk Investigational Site

    La Mesa, California

  • Novo Nordisk Investigational Site

    Lancaster, California

  • Novo Nordisk Investigational Site

    Monterey, California

  • Novo Nordisk Investigational Site

    San Mateo, California

  • Novo Nordisk Investigational Site

    San Ramon, California

  • Novo Nordisk Investigational Site

    Walnut Creek, California

  • Novo Nordisk Investigational Site

    Denver, Colorado

  • Novo Nordisk Investigational Site

    Fort Lauderdale, Florida

  • Novo Nordisk Investigational Site

    Hialeah, Florida

  • Novo Nordisk Investigational Site

    Jacksonville, Florida

  • Novo Nordisk Investigational Site

    Tampa, Florida

  • Novo Nordisk Investigational Site

    Atlanta, Georgia

  • Novo Nordisk Investigational Site

    Atlanta, Georgia

  • Novo Nordisk Investigational Site

    Marietta, Georgia

  • Novo Nordisk Investigational Site

    Roswell, Georgia

  • Novo Nordisk Investigational Site

    Savannah, Georgia

  • Novo Nordisk Investigational Site

    Idaho Falls, Idaho

  • Novo Nordisk Investigational Site

    Indianapolis, Indiana

  • Novo Nordisk Investigational Site

    Council Bluffs, Iowa

  • Novo Nordisk Investigational Site

    Iowa City, Iowa

  • Novo Nordisk Investigational Site

    Topeka, Kansas

  • Novo Nordisk Investigational Site

    Metarie, Louisiana

  • Novo Nordisk Investigational Site

    Baltimore, Maryland

  • Novo Nordisk Investigational Site

    Minneapolis, Minnesota

  • Novo Nordisk Investigational Site

    Chesterfield, Missouri

  • Novo Nordisk Investigational Site

    City of Saint Peters, Missouri

  • Novo Nordisk Investigational Site

    Saint Charles, Missouri

  • Novo Nordisk Investigational Site

    Springfield, Missouri

  • Novo Nordisk Investigational Site

    St Louis, Missouri

  • Novo Nordisk Investigational Site

    Billings, Montana

  • Novo Nordisk Investigational Site

    Butte, Montana

  • Novo Nordisk Investigational Site

    Lawrenceville, New Jersey

  • Novo Nordisk Investigational Site

    Albany, New York

  • Novo Nordisk Investigational Site

    Mineola, New York

  • Novo Nordisk Investigational Site

    New York, New York

Showing 40 of 182 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.